Compare DFIN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | IVA |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 991.6M | 883.8M |
| IPO Year | 2017 | N/A |
| Metric | DFIN | IVA |
|---|---|---|
| Price | $40.63 | $3.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $61.50 | $16.20 |
| AVG Volume (30 Days) | 368.4K | ★ 935.4K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $963,000,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $3.87 | $751.20 |
| P/E Ratio | $31.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.11 | $2.94 |
| 52 Week High | $66.25 | $7.98 |
| Indicator | DFIN | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 31.77 |
| Support Level | $36.78 | N/A |
| Resistance Level | $41.22 | $4.67 |
| Average True Range (ATR) | 1.71 | 0.21 |
| MACD | 0.52 | -0.00 |
| Stochastic Oscillator | 78.46 | 2.02 |
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.